132 related articles for article (PubMed ID: 24256655)
21. Radiotherapy planning.
Truong MT; Kovalchuk N
PET Clin; 2015 Apr; 10(2):279-96. PubMed ID: 25829092
[TBL] [Abstract][Full Text] [Related]
22. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
[TBL] [Abstract][Full Text] [Related]
23. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
24. Dose tracking assessment for image-guided radiotherapy of the prostate bed and the impact on clinical workflow.
Orlandini LC; Coppola M; Fulcheri C; Cernusco L; Wang P; Cionini L
Radiat Oncol; 2017 Apr; 12(1):78. PubMed ID: 28454559
[TBL] [Abstract][Full Text] [Related]
25. Dosimetric comparison of stopping power calibration with dual-energy CT and single-energy CT in proton therapy treatment planning.
Zhu J; Penfold SN
Med Phys; 2016 Jun; 43(6):2845-2854. PubMed ID: 27277033
[TBL] [Abstract][Full Text] [Related]
26. Intensity-modulated radiotherapy of prostate cancer with simultaneous integrated boost after molecular imaging with 18F-choline-PET/CT : Clinical results and quality of life.
Schlenter M; Berneking V; Krenkel B; Mottaghy FM; Vögeli TA; Eble MJ; Pinkawa M
Strahlenther Onkol; 2018 Jul; 194(7):638-645. PubMed ID: 29511777
[TBL] [Abstract][Full Text] [Related]
27. Primary Cardiac Angiosarcoma Treated With Positron Emission Tomography/Magnetic Resonance Imaging-Guided Adaptive Radiotherapy.
Elsayad K; Lehrich P; Yppaerilae-Wolters H; Dieckmann C; Kriz J; Haverkamp U; Eich HT
Can J Cardiol; 2016 Jun; 32(6):829.e7-829.e10. PubMed ID: 26514752
[TBL] [Abstract][Full Text] [Related]
28. PET and PET/CT in radiation treatment planning for prostate cancer.
Pinkawa M; Eble MJ; Mottaghy FM
Expert Rev Anticancer Ther; 2011 Jul; 11(7):1033-9. PubMed ID: 21806327
[TBL] [Abstract][Full Text] [Related]
29. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
[TBL] [Abstract][Full Text] [Related]
30. [Radiotherapy promises: focus on lung cancer].
Jouin A; Durand-Labrunie J; Leroy T; Pannier D; Wagner A; Rault E; Lartigau E
Bull Cancer; 2013 Jun; 100(6):575-85. PubMed ID: 23719541
[TBL] [Abstract][Full Text] [Related]
31. Robust PET-guided intensity-modulated radiation therapy.
Li H; Bissonnette JP; Purdie T; Chan TC
Med Phys; 2015 Aug; 42(8):4863-71. PubMed ID: 26233213
[TBL] [Abstract][Full Text] [Related]
32. Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets.
Yoder AK; Gunther JR; Milgrom SA; Pham M; Hancock D; McSpadden K; Garcia J; Mirkovic D; Dabaja BS; Pinnix CC
Pract Radiat Oncol; 2019 May; 9(3):147-152. PubMed ID: 30708131
[TBL] [Abstract][Full Text] [Related]
33. A GPU-accelerated and Monte Carlo-based intensity modulated proton therapy optimization system.
Ma J; Beltran C; Seum Wan Chan Tseung H; Herman MG
Med Phys; 2014 Dec; 41(12):121707. PubMed ID: 25471954
[TBL] [Abstract][Full Text] [Related]
34. Assessing patient outcomes after palliative radiotherapy using image-guided intensity-modulated radiotherapy.
Samant R; Scopazzi M; Carty K
Clin Oncol (R Coll Radiol); 2012 Oct; 24(8):e125. PubMed ID: 22525005
[No Abstract] [Full Text] [Related]
35. Intensity modulated proton therapy.
Kooy HM; Grassberger C
Br J Radiol; 2015 Jul; 88(1051):20150195. PubMed ID: 26084352
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of CBCT-based proton dose calculation using a histogram-matching algorithm in proton beam therapy.
Arai K; Kadoya N; Kato T; Endo H; Komori S; Abe Y; Nakamura T; Wada H; Kikuchi Y; Takai Y; Jingu K
Phys Med; 2017 Jan; 33():68-76. PubMed ID: 27998666
[TBL] [Abstract][Full Text] [Related]
37. Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors.
Park J; Park Y; Lee SU; Kim T; Choi YK; Kim JY
Radiat Oncol; 2015 Jun; 10():135. PubMed ID: 26112360
[TBL] [Abstract][Full Text] [Related]
38. Towards a novel small animal proton irradiation platform: the SIRMIO project.
Parodi K; Assmann W; Belka C; Bortfeldt J; Clevert DA; Dedes G; Kalunga R; Kundel S; Kurichiyanil N; Lämmer P; Lascaud J; Lauber K; Lovatti G; Meyer S; Nitta M; Pinto M; Safari MJ; Schnürle K; Schreiber J; Thirolf PG; Wieser HP; Würl M
Acta Oncol; 2019 Oct; 58(10):1470-1475. PubMed ID: 31271091
[No Abstract] [Full Text] [Related]
39. Degradation of target coverage due to inter-fraction motion during intensity-modulated proton therapy of prostate and elective targets.
Thörnqvist S; Muren LP; Bentzen L; Hysing LB; Høyer M; Grau C; Petersen JB
Acta Oncol; 2013 Apr; 52(3):521-7. PubMed ID: 23409771
[TBL] [Abstract][Full Text] [Related]
40. [Advances in research on biological target volume and conformal intensity-modulated radiotherapy].
Yu JM; Chen SQ
Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):801-3. PubMed ID: 17415998
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
